Marc Beer is a co-founder of Renovia Inc., and the company’s current chairman and Chief Executive Officer. The company recently managed to secure $32 million in Series B round as well as $10 million in venture debt. Renovia is a medical technology company, focused on developing products which can diagnose as well as treat urinary incontinence, which is a pelvic floor disorder that affects up to 250 million women worldwide. Learn more: https://www.linkedin.com/in/marcbeer
When the company announced the funding, Marc Beer mentioned his appreciation for the group of leading healthcare investors that participated. Longwood Fund is an investing group which focuses on healthcare issues, and is an early backer of Renovia, while the series B round was led by the Ascension Venutres and the Perceptive Advisers. Renovia’s first product, Leva, was approved by the Food and Drug Administration back in April of this year, and the new finances will support the development as well as testing of four products, Beer pointing out his intention to produce a new generation of Leva. According to Marc beer, the increased understanding when it comes to pelvic floor disorders could lead to the lowering of long-term healthcare costs.
Renovia was founded in 2016 by Marc Beer alongside Yolanda Lorie and Ramon Iglesias. Marc Beer’s academic track record includes a B.S. degree earned from the Miami University in 1987. Prior to co-founding Renovia, Marc Beer already earned a reputation within the healthcare sector. In April of 2000 he was the Founding Chief Executive Officer of ViaCell, a biotechnology company which specialized in the collection, preservation and development of blood stem cells from umbilical cords. The company grew in quick fashion, hiring over 300 employees and going public in 2005, before ultimately being acquired by PerkinElmer only 7 years after its inception, in 2007.
Besides his role at ViaCell, Marc Beer was also a member of the board of directors of Erytech Pharma, a publicly traded pharmaceuticals company, he served as the vice president of global marketing for Genzyme, founded Good Start Genetics, and held different executive roles at various companies within the healthcare industry. Genzyme focused on gene-based applications which treaded various rare disorders, and from his VP role in the company Beer was responsible for the launch of several products which addressed rare disease populations around the globe.
Before working for Genzyme, Marc beer was a member of the Mass Life Science Board at the Commonwealth of Massachusetts, and he served Emerging Companies Section Governing Board at BIO (Biotechnology Industry Organization). Additionally, he currently has ties with Minerva Neurosciences, acting as the Founding Chairman of the board, member of the audit committee, and chairman of the compensation committee. He is also currently a member of the Miami University Business Advisory Council.